Journal
PPAR RESEARCH
Volume 2010, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2010/814609
Keywords
-
Categories
Funding
- National Institutes of Health [EY-017123, ES-01247, DE-011390, HL-078603, T32 DE007202]
- Research to Prevent Blindness, Rochester Eye and Tissue Bank [0655897T]
- American Heart Association Founders Affiliate
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T90DE021985] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The use of targeted cancer therapies in combination with conventional chemotherapeutic agents and/or radiation treatment has increased overall survival of cancer patients. However, longer survival is accompanied by increased incidence of comorbidities due, in part, to drug side effects and toxicities. It is well accepted that inflammation and tumorigenesis are linked. Because peroxisome proliferator-activated receptor (PPAR)-gamma agonists are potent mediators of anti-inflammatory responses, it was a logical extension to examine the role of PPAR gamma agonists in the treatment and prevention of cancer. This paper has two objectives: first to highlight the potential uses for PPAR gamma agonists in anticancer therapy with special emphasis on their role when used as adjuvant or combined therapy in the treatment of hematological malignancies found in the vasculature, marrow, and eyes, and second, to review the potential role PPAR. and/or its ligands may have in modulating cancer-associated angiogenesis and tumor-stromal microenvironment crosstalk in bone marrow.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available